At its July meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of 14 new medicines, highlighting three biosimilars and four orphan medicines. Biosimilars include Fresenius Kabi's Tyenne (tocilizumab) to treat rheumatoid arthritis and other disorders, Sandoz's Tyruko (natalizumab) for multiple sclerosis, and Viatris' Yesafili (aflibercept) for age-related macular degeneration. Once authorized by the European Commission, these medicines will increase the active ingredients available in the European Union to 22. As for orphan drugs, Otsuka's Inaqovi (decitabine/cedazuridine) has been recommended to treat acute myeloid leukemia, Janssen's Talvey (talquetamab) for relapsed and refractory multiple myeloma, Abbvie's Tepkinly (epcoritamab) for diffuse lymphoma large B-cell cancer and Novartis' Tevimbra (tislelizumab) for squamous cell esophageal cancer.

READ MORE